Mathematics · Statistics and Probability
Recent Discussions on Statistical Analysis Methods in Cancer Clinical Trials and Their Application to Pharmaceutical Sciences:
Miki Horiguchi, Yuji Yoshiyama
See on the mapAbstract
Randomized controlled trials (RCTs) are the key method to investigate the treatment effect with methodologic rigor. An essential goal of RCTs is to provide robust and interpretable quantitative information about the treatment effect for clinicians/patients to balance risk/benefit and make a treatment decision. However, for time-to-event outcomes, such as overall survival or progression-free survival in cancer trials, the present analytic practice that routinely uses the hazard ratio for summarizing the magnitude of the treatment effect has significant limitations, which makes it harder to achieve the goal. The issues of hazard ratio and several good alternatives (such as difference or ratio of t-year event rates, median, and restricted mean survival time) have been extensively discussed in recent medical journals. In this paper, we highlight these recent discussions, introducing the reports of three RCTs published in major oncology journals and the letter-to-editor for each of the three RCTs. We conclude that choosing a robust and interpretable metric, rather than simply relying on the routine hazard ratio approach, would be important for summarizing the treatment effect in future clinical trials with time-to-event outcomes, which will ultimately foster better informed treatment decision making.